Recombinant Human Prourokinase

DRUG2 trials

Sponsors

Tasly Biopharmaceuticals Co., Ltd., The First Affiliated Hospital of Anhui Medical University

Conditions

Acute Ischemic StrokeAcute Pulmonary Embolism

Phase 2

A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism

CompletedNCT03108833

Tasly Biopharmaceuticals Co., Ltd.Acute Pulmonary Embolism

Start: 2017-06-06End: 2019-12-19Updated: 2021-03-18

Unknown Phase

Real-World Evaluation of Recombinant Human Prourokinase for Acute Ischemic Stroke Within 4.5 Hours

Not yet recruitingNCT07787325

The First Affiliated Hospital of Anhui Medical UniversityAcute Ischemic Stroke

Start: 2026-09-11End: 2029-08-31Target: 3000Updated: 2026-08-26